Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 5, 2011, Pages 985-994

  Ng, Chee M ^a,c   Patnaik, A ^b   Beeram, M ^b   Lin, C C ^a,d   Takimoto, C H ^b  

^a CTRC Institute for Drug Development   (United States)

^b South Texas Accelerated Research Therapeutics   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cancer; Model; Pharmacodynamics; Pharmacokinetics; Phase I study; Troxacitabine

Indexed keywords

CISPLATIN; TROXACITABINE;

ADULT; AGED; ALGORITHM; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARTMENT MODEL; COMPUTER ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; FEEDBACK SYSTEM; HUMAN; INCIDENCE; NEUTROPENIA; NEUTROPHIL; NEUTROPHIL COUNT; PHARMACODYNAMICS; PRIORITY JOURNAL; SIMULATION; STEM CELL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTOSINE; DIOXOLANES; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NEOPLASMS; NEUTROPENIA; YOUNG ADULT;

EID: 79955567868     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1393-y     Document Type: Article

References (26)

1. Bauer RJ, Guzy S (2004) Monte Carlo Parametric Expectation Maximization (MC-PEM) method for analyzing population pharmacokinetic/pharmacodynamic (PK/PD) data. In: D'Argenio DZ (ed) Advanced methods of pharmacokinetic and pharmacodynamic system analysis. Kluwer, Boston, pp 135-163
2. SL Beal LB Sheiner 1980 The NONMEM System Am Stat 34 118 119 10.2307/2684123
3. K Belanger M Moore SD Baker J Dionne M Maclean J Jolivet L Siu D Soulieres N Wainman L Seymour 2002 Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-min infusion every 21 days J Clin Oncol 20 2567 2574 12011137 10.1200/JCO.2002.12.047 1:CAS:528: DC%2BD38XksFaku7w%3D (Pubitemid 34525745)
4. Carroll RJ, Ruppert D (1988) Transformation and weighting in regression. Chapman and Hall, New York
5. GE Cartwright JW Athens MM Wintrobe 1964 The kinetics of granulopoiesis in normal man Blood 24 780 803 14235362 1:STN:280:DyaF2M%2FjvFOkug%3D%3D
6. KK Chary DJ Higby ES Henderson KD Swinerton 1977 Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis Cancer Treat Rep 61 367 370 266972 1:CAS:528:DyaE2sXkslyiu70%3D (Pubitemid 8137938)
7. Davidian M, Giltinan DM (1995) Nonlinear models for repeated measures data. Chapman and Hall, New York
8. JS de Bono J Stephenson Jr SD Baker M Hidalgo A Patnaik LA Hammond G Weiss A Goetz L Siu C Simmons J Jolivet EK Rowinsky 2002 Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies J Clin Oncol 20 96 109 11773159 10.1200/JCO.20.1.96 (Pubitemid 34032601)
9. LE Friberg A Henningsson H Maas L Nguyen MO Karlsson 2002 Model of chemotherapy-induced myelosuppression with parameter consistency across drugs J Clin Oncol 20 4713 4721 12488418 10.1200/JCO.2002.02.140 (Pubitemid 36025290)
10. LE Friberg MO Karlsson 2003 Mechanistic models for myelosuppression Invest New Drugs 21 183 194 12889739 10.1023/A:1023573429626 1:CAS:528:DC%2BD3sXjtlantrc%3D (Pubitemid 36859318)
11. CM Galmarini JR Mackey C Dumontet 2001 Nucleoside analogues: mechanisms of drug resistance and reversal strategies Leukemia 15 875 890 11417472 10.1038/sj.leu.2402114 1:CAS:528:DC%2BD3MXkvVOit78%3D (Pubitemid 32529886)
12. Gelman A, Meng XL (1996) Model checking and model improvement. In: Gilks WR, Richardson S, Spiegelhalter DJ (eds) Markov chain monte carlo in practice. Chapman and Hall/CRC, Boca Raton, pp 189-202
13. FJ Giles JE Cortes SD Baker DA Thomas S O'Brien TL Smith M Beran C Bivins J Jolivet HM Kantarjian 2001 Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia J Clin Oncol 19 762 771 11157029 1:CAS:528:DC%2BD3MXhtlGrt7w%3D (Pubitemid 32119091)
14. KL Grove YC Cheng 1996 Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells Cancer Res 56 4187 4191 8797590 1:CAS:528:DyaK28XlslGgtrY%3D (Pubitemid 26305014)
15. KL Grove X Guo SH Liu Z Gao CK Chu YC Cheng 1995 Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration Cancer Res 55 3008 3011 7606719 1:CAS:528:DyaK2MXmvVyitr0%3D
16. E Kuhn M Lavielle 2005 Maximum likelihood estimation in nonlinear mixed effects models Comput Statist Data Anal 49 1020 1038 10.1016/j.csda.2004.07.002 (Pubitemid 40710158)
17. JE Latz MO Karlsson JJ Rusthoven A Ghosh RD Johnson 2006 A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy Cancer Chemother Pharmacol 57 412 426 16322990 10.1007/s00280-005-0077-5 (Pubitemid 43087584)
18. M Lavielle F Mentre 2007 Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software J Pharmacokinet Pharmacodyn 34 229 249 17211713 10.1007/s10928-006-9043-z 1:CAS:528:DC%2BD2sXjs1ektb8%3D (Pubitemid 46536259)
19. CK Lee EK Rowinsky J Li F Giles MJ Moore M Hidalgo E Capparelli J Jolivet SD Baker 2006 Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue Clin Cancer Res 12 2158 2165 16609029 10.1158/1078-0432.CCR- 05-2249 1:CAS:528:DC%2BD28XjtlChs78%3D
20. CC Lin M Beeram EK Rowinsky CH Takimoto CM Ng CE Geyer Jr LJ Denis JS De Bono D Hao AW Tolcher SY Rha J Jolivet A Patnaik 2009 Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies Cancer Chemother Pharmacol 65 167 175 19449006 10.1007/s00280-009-1020-y 1:CAS:528: DC%2BD1MXhtFegurbO
21. CM Ng A Joshi RL Dedrick MR Garovoy RJ Bauer 2005 Pharmacokinetic- pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis Pharm Res 22 1088 1100 16028009 10.1007/s11095-005-5642-4 1:CAS:528:DC%2BD2MXmt1yntbw%3D (Pubitemid 41127066)
22. AW Prestayko JC D'Aoust BF Issell ST Crooke 1979 Cisplatin (cis-diamminedichloroplatinum II) Cancer Treat Rev 6 17 39 378370 10.1016/S0305-7372(79)80057-2 1:STN:280:DyaE1M3htFSntA%3D%3D (Pubitemid 9189580)
23. Schumitzky A (1995) EM algorithms and two stage methods in pharmacokinetic population analysis. In: D'Argenio DZ (ed) Advanced methods of pharmacokinetic and pharmacodynamic system analysis. Plenum Press, New York, pp 145-160
24. RW Talley RM O'Bryan JU Gutterman RW Brownlee KB McCredie 1973 Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)-phase I clinical study Cancer Chemother Rep 57 465 471 4762440 1:STN:280: DyaE2c%2FltlSlsg%3D%3D
25. S Walker 1996 An EM algorithm for nonlinear random effects models Biometrics 52 934 944 10.2307/2533054 (Pubitemid 26296070)
26. Y Yano SL Beal LB Sheiner 2001 Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check J Pharmacokinet Pharmacodyn 28 171 192 11381569 10.1023/A:1011555016423 1:STN:280:DC%2BD38%2FhtV2htg%3D%3D (Pubitemid 33030044)